Atea stockholders reelect all three Class III directors; KPMG ratified; say-on-pay passes

Atea Pharmaceuticals, Inc.

Jerome Adams, Howard Berman, Barbara Duncan elected as Class III directors (for votes: 28.8M, 44.5M, 43.7M).
Ratification of KPMG as auditor for FY2026: 58.9M for, 0.78M against, 65.5K abstain.
Advisory approval of exec compensation: 47.5M for, 3.0M against, 643.6K abstain; broker non-vote 8.7M.
Approximately 74.65% of outstanding shares represented at the meeting (59.7M shares).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Atea Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-18 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-18

Exact text from the filing

Proposal 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. FOR AGAINST ABSTAIN BROKER NON-VOTE 58,894,207 783,081 65,531 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Atea Pharmaceuticals, Inc. shareholders approved Election of three Class III Directors to serve until the 2029 annual meeting of stockholders, and until their respective successors have been duly elected and qualified. at the 2026-06-18 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-18

Exact text from the filing

Proposal 1 — Election of three Class III Directors to serve until the 2029 annual meeting of stockholders, and until their respective successors have been duly elected and qualified. FOR WITHHOLD BROKER NON-VOTE Jerome Adams, MD, MPH 28,798,012 22,275,665 8,669,142 Howard Berman, PhD 44,466,627 6,607,050 8,669,142 Barbara Duncan 43,697,098 7,376,579 8,669,142

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Atea Pharmaceuticals, Inc. shareholders approved Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. at the 2026-06-18 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-18

Exact text from the filing

Proposal 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. FOR AGAINST ABSTAIN BROKER NON-VOTE 47,452,759 2,977,290 643,628 8,669,142

View on SEC.gov

1183 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-277639

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.